How to cite item

Brigatinib entering the clinic for ALK rearranged metastatic NSCLC: editorial on a randomized multicenter phase II study with two brigatinib dose regimens

   
@article{TCR15257,
	author = {Adrianus J. de Langen},
	title = {Brigatinib entering the clinic for ALK rearranged metastatic NSCLC: editorial on a randomized multicenter phase II study with two brigatinib dose regimens},
	journal = {Translational Cancer Research},
	volume = {6},
	number = {Suppl 6},
	year = {2017},
	keywords = {},
	abstract = {In ~5% of patients with non-small-cell lung cancer (NSCLC), the disease is characterized by an anaplastic lymphoma kinase (ALK) rearrangement (1,2). In 2011 the Food and Drug Administration granted Crizotinib, an ALK tyrosine kinase inhibitor (TKI), accelerated approval based on durable objective response rates (ORR) of 50 percent and 61 percent in two single-arm open-label studies (3-5). A signal that was confirmed in a randomized phase III study where crizotinib showed superior outcome when compared to pemetrexed or docetaxel monotherapy in patients that progressed after platinum doublet chemotherapy (6).},
	issn = {2219-6803},	url = {https://tcr.amegroups.org/article/view/15257}
}